• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

First Canine Therapeutic Drug for Pancreatitis Approved

October 3, 2018
Kerry Lengyel

Now approved in Japan, BRENDA is the first drug of its kind to safely and effectively reduce the clinical signs associated with acute pancreatitis in dogs.

After a lengthy approval process, a new drug has received approval in Japan for the management of pancreatitis in dogs. BRENDA—which stands for blood cell response to endothelial cell non-adhesion—is believed to be the first drug of its kind for use by veterinarians to safely and effectively reduce the clinical signs associated with the disease.

“Canine pancreatitis brings the possibility of mortality,” said Hiroshi Shikama, PhD, general manager of the research and development division at Ishihara Sangyo Kaisha (ISK) Animal Health Headquarters, the drug’s manufacturer. “Until now, the only treatment available to veterinarians was to mitigate symptoms of pancreatitis with things such as anti-emetics, fluid support, pain control, and so forth.”

RELATED:

  • Survival Times of Dogs with Pituitary-Dependent Hyperadrenocorticism With and Without Treatment
  • Critical Care Nutrition
Advertisement

BRENDA is ISK’s first venture into the animal health pharmaceutical industry. According to Dr. Shikama, the company saw an opportunity and need to apply its years of science and expertise to help find a better solution for managing the condition.

“BRENDA has a critical drug efficacy for acute pancreatitis,” he said, “allowing for a speedier recovery and decreased likelihood of long-term damage.”

Clinical studies for the drug ran from June 2015 through February 2016. Accordingly, they filed for approval to the Japanese Ministry of Agriculture, Forestry, and Fisheries in May 2016 and received approval in late September.

“In Japan, there are few therapeutic drugs available for companion animals,” Dr. Shikama said, “so we were motivated to explore these possibilities.”

BRENDA is being launched in the Japanese market first, with the intention of obtaining approval in other markets over time. The company has already begun the FDA approval process in the United States and has been assigned an Investigational New Animal Drug file number for clinical studies.

“We are running a pilot clinical study to prove the efficacy of regimen,” Dr. Shikama said. “The next step will be a pivotal clinical study, which we are aiming to start May 2019.”


Advertisement

Latest News

Comparing treatments for restoring the skin barrier in atopic dogs

Increasing efficiency and productivity in uncertain times

AAVMC awards almost $100,000 in diversity scholarships

News wrap-up: This week’s headlines, plus Maryland Zoo welcomes baby addra gazelle

View More Latest News
Advertisement